Cargando…

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion

Sickle cell disease is characterized by chronic anemia and vaso-occlusive crises, which eventually lead to multi-organ damage and premature death. Hematopoietic stem cell transplantation is the only curative treatment but it is limited by toxicity and poor availability of HLA-compatible donors. A ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagresle-Peyrou, Chantal, Lefrère, François, Magrin, Elisa, Ribeil, Jean-Antoine, Romano, Oriana, Weber, Leslie, Magnani, Alessandra, Sadek, Hanem, Plantier, Clémence, Gabrion, Aurélie, Ternaux, Brigitte, Félix, Tristan, Couzin, Chloé, Stanislas, Aurélie, Tréluyer, Jean-Marc, Lamhaut, Lionel, Joseph, Laure, Delville, Marianne, Miccio, Annarita, André-Schmutz, Isabelle, Cavazzana, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927997/ https://www.ncbi.nlm.nih.gov/pubmed/29472357 http://dx.doi.org/10.3324/haematol.2017.184788

Ejemplares similares

Transfusion‐related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory
por: Ribeil, Jean‐Antoine, et al.
Publicado: (2018)

A Nontoxic Transduction Enhancer Enables Highly Efficient Lentiviral Transduction of Primary Murine T Cells and Hematopoietic Stem Cells
por: Delville, Marianne, et al.
Publicado: (2018)

Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy
por: Magnani, Alessandra, et al.
Publicado: (2020)

Human T-Lymphoid Progenitors Generated in a Feeder-Cell-Free Delta-Like-4 Culture System Promote T-Cell Reconstitution in NOD/SCID/γc(−/−) Mice
por: Reimann, Christian, et al.
Publicado: (2012)

An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype
por: Weber, Leslie, et al.
Publicado: (2018)

Generation of adult human T-cell progenitors for immunotherapeutic applications
por: Simons, Laura, et al.
Publicado: (2018)

Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy
por: Sobrino, Steicy, et al.
Publicado: (2023)

A gain-of-function RAC2 mutation is associated with bone marrow hypoplasia and an autosomal dominant form of severe combined immunodeficiency
por: Lagresle-Peyrou, Chantal, et al.
Publicado: (2020)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Bayesian Modeling Immune Reconstitution Apply to CD34+ Selected Stem Cell Transplantation for Severe Combined Immunodeficiency
por: Diana, Jean-Sebastien, et al.
Publicado: (2022)

AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages
por: Six, E, et al.
Publicado: (2015)

An Evaluation of Three Ways of Communicating Carrier Status Results to the Parents of Children in a Neonatal Sickle Cell Screening Programme
por: Rémus, Christelle, et al.
Publicado: (2020)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Concise Review: Epigenetic Regulation of Hematopoiesis: Biological Insights and Therapeutic Applications
por: Antoniani, Chiara, et al.
Publicado: (2017)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Safety of CD34(+) Hematopoietic Stem Cells and CD4(+) T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma
por: Delville, Marianne, et al.
Publicado: (2019)

Hematopoietic Stem Cell Transplant for the Treatment of X-MAID
por: Henrickson, Sarah E., et al.
Publicado: (2019)

Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID
por: Charrier, Sabine, et al.
Publicado: (2019)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population
por: Sebastien, Bernard, et al.
Publicado: (2022)

DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer
por: Wang, Gary P., et al.
Publicado: (2008)

A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency
por: Thouenon, Romane, et al.
Publicado: (2023)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

S265: MATERNAL AND PERINATAL OUTCOMES OF SICKLE CELL DISEASE IN PREGNANCY: A NATIONWIDE STUDY IN FRANCE.
por: Corsia, Alice, et al.
Publicado: (2023)

S274: A NEW, EFFECTIVE, SAFE, NON-MYELOABLATIVE CONDITIONING REGIMEN WITH A HLA-MATCHED SIBLING DONOR FOR THE SEVERE SICKLE CELL PHENOTYPE IN ADULTS
por: Ihlem, Rahal, et al.
Publicado: (2023)

Optical deformability of fluid interfaces
por: Delville, Jean-Pierre
Publicado: (2009)

Genome Editing for β-Hemoglobinopathies: Advances and Challenges
por: Frati, Giacomo, et al.
Publicado: (2021)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

PB2514: IMMUNOGENICITY OF ANTI-SARS-COV-2 VACCINES IN PATIENTS WITH SEVERE SICKLE CELL DISEASE
por: Meunier, Benoit, et al.
Publicado: (2023)

Adenine base editor–mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation
por: Hardouin, Giulia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a88h9ll7kgab6tai6okdean4vo